To the Editor-We thank Chart et al. [1] for demonstrating that an EIA to the Escherichia coli O55 lipopolysaccharide (O55 LPS) can be made more specific than previously suggested in our communication [2] . In our paper, we reported that early serum samples from approximately one-third of the children with acute hemolytic uremic syndrome (HUS) associated with infection by E. coli O157 reacted with O55 LPS in an indirect EIA using a commercial LPS preparation from an E. coli O55: B5 strain (Paesel & Lorey, Frankfurt, Germany) as antigen [2] . This observation was unexpected, since rabbit immune serum specific for E. coli O55 LPS (Behringwerke, Marburg, Germany), elicited with LPS from E. coli O55:K59, did not recognize E. coli O157 LPS. Conversely, rabbit immune serum to O157 LPS failed to bind to O55 LPS, a finding confirmed by Chart et al. [1] . Furthermore, we did not detect antibodies to E. coli O157 LPS in sera from 2 patients with HUS with cultureproven infection by verotoxin-producing E. coli (VTEC) O55: HϪ and O55:H6 [2] . On the basis of the low incidence of VTEC O55 isolates from patients with HUS in Germany [2], we considered unrecognized coinfections by both E. coli O157 and O55 strains in this many patients to be an unlikely explanation for the high prevalence of positive O55 LPS ELISA results. Instead, we proposed that E. coli O157 strains might induce antibodies to an epitope of E. coli O55 in a subset of patients. We raised the possibility that the close evolutionary proximity between enteropathogenic E. coli O55:H7 and VT-producing E. coli O157 clones [3, 4] might result in the expression of homologous LPS epitopes and give rise to the observed crossreactivity. Further inquiries regarding the source and original serotype of the E. coli O55 LPS preparation used in our study were not successful. However, the E. coli O55:B5 strain used to purify another O55 LPS preparation (Difco, Detroit) was described by the manufacturer (personal communication) as weakly motile or nonmotile. It would be interesting to directly compare our commercial LPS with the E. coli O55 preparations and SDS profiles used by Chart et al. [1] .
Strains of Escherichia coli Belonging to Serogroups O157 and O55 Express Lipopolysaccharides That Are Structurally Distinct and Do Not Share Common Epitopes
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We recently learned of a report by Lindberg et al. [5] , who identified the structure of the O55 LPS. The structures of the reported E. coli O157 LPS [6] and the O55 LPS differ. A serologic study using a panel of monoclonal antibodies to the O antigen and to the core antigen of E. coli O157:H7 (strain CDC EDL 933), while confirming the cross-reactivity with Salmonella group N O30 antigens, failed to recognize E. coli O55: H7 by ELISA [7] . Therefore, we no longer believe that the cross-reactivity we observed was caused by structural similarity between the O antigens of these two E. coli serogroups.
A recent paper [8] demonstrated that a rough mutant of E. coli O157 was reactive in an EIA (LMD Laboratories, Sunnyvale, CA) and an agglutination assay kit (Denka Seiken, Tokyo), specific for organisms expressing the O157 antigen. This raises the possibility that a bacterial antigen copurified with LPS might be detected by animals immunized with the E. coli O157 LPS. Laegreid et al. [9] , for example, reported the generation of a monoclonal antibody against E. coli O157:H7, which recognized various non-O157 E. coli serotypes, including E. coli O55:H7. If patients' immune responses to the(se) as yet unknown antigen(s) are similar and the LPS we used from E. coli O55:B5 contains this antigen, then the cross-reactivity might be explained on this basis. The isolation of variant, immotile, and/or sorbitol-fermenting VTEC O157 strains from HUS patients in Germany [10] and, more recently, in the Czech Republic [11] has now been well documented. One could test the hypothesis that this heterogeneity in clinically relevant, endemic E. coli O157 strains results in heterogenic immune responses in different populations to a set of LPS O157 [1] and protein surface antigens expressed by various E. coli O157 clones [4, 12] . 
Martin Bitzan and Kerstin Ludwig

